Off-label use of orphan medicinal products: a Belgian qualitative study

Orphanet Journal of Rare Diseases has published a paper about the off-label use of orphan medicinal products for rare diseases in Belgium. The study included semi-structured interviews with seven physicians with expertise in the treatment with and six experts in the reimbursement of orphan medicinal products in Belgium. Most participants do agree with the off-label use if the medicinal product is quite safe and well-tolerated, if the on-label indication is rather general and when all other options have failed in some specific, evidence-based indications, especially in children.  The full-text article is available here.